141 related articles for article (PubMed ID: 30771871)
1. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Li J; Gu J
Crit Rev Oncol Hematol; 2019 Feb; 134():31-38. PubMed ID: 30771871
[TBL] [Abstract][Full Text] [Related]
2. Fatigue with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Li J; Sun W
J Chemother; 2018; 30(6-8):323-331. PubMed ID: 30663550
[TBL] [Abstract][Full Text] [Related]
3. Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
Yin X; Zhao Z; Yin Y; Shen C; Chen X; Cai Z; Wang J; Chen Z; Yin Y; Zhang B
Clin Transl Sci; 2021 May; 14(3):919-933. PubMed ID: 33382906
[TBL] [Abstract][Full Text] [Related]
4. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
5. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Li J; Gu J
Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
[TBL] [Abstract][Full Text] [Related]
6. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
Li J; Gu J
Crit Rev Oncol Hematol; 2017 Nov; 119():50-58. PubMed ID: 29065985
[TBL] [Abstract][Full Text] [Related]
7. Diarrhea With HER2-Targeted Agents in Cancer Patients: A Systematic Review and Meta-Analysis.
Li J
J Clin Pharmacol; 2019 Jul; 59(7):935-946. PubMed ID: 30707455
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
Li J; Gu J
Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
[TBL] [Abstract][Full Text] [Related]
9. Risk of Thrombocytopenia With Platelet-Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized, Controlled Trials.
Liu Y; Sun W; Li J
J Clin Pharmacol; 2021 Nov; 61(11):1397-1405. PubMed ID: 34241895
[TBL] [Abstract][Full Text] [Related]
10. Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhang X; Ran YG; Wang KJ
Future Oncol; 2016 Dec; 12(23):2741-2753. PubMed ID: 27522860
[TBL] [Abstract][Full Text] [Related]
11. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Gu J
Eur J Clin Pharmacol; 2017 Oct; 73(10):1209-1217. PubMed ID: 28710508
[TBL] [Abstract][Full Text] [Related]
12. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
13. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Liu J; Sheng Z; Zhang Y; Li G
Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Wang Y; Wang M; Wang Q; Geng Z; Sun M
Oncotarget; 2017 Apr; 8(17):29406-29415. PubMed ID: 28107192
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
